CLRO ClearOne Inc

$CLRO It has a signed reverse merger with Cortigent (Vivani Medical / $VANI subsidiary) — neurostimulation, visual prosthesis, and stroke-recovery implants. The deal is expected to price and close in October. Combined company would be renamed Cortigent Holdings and trade as CRGT. Existing CLRO holders would own only ~13–14% of the new entity; Vivani gets 12.5M shares

💵Some Stocks to Watch for 28 Sept: $CLRO $GYGY $MIMI $INLF $MX.X MSGY AIFF APUS 🔥Below are results from Friday and this month. 👉See Profile for Reviews and to Join Us.

$CLRO Almost THREE-FIFTHS of today's off-exchange VOLUME was SHORT SALES. This ratio was likely much higher during the LOW-LIQUIDITY PULLBACKs, as some usual short tactics aim to artificially drive the price down and trick people into surrendering their shares. The on-screen price has significantly diverged from the session's VWAP, which is much higher. Also, shorts have depleted borrowable shares and likely recycled the same shares through short-to-short trades, while the CTB has stayed above 200% for weeks. Float is less than 1M. IBKR had 100k available shares in June; now there are NONE. This data comes from only one broker. In total, there may be tens or hundreds of thousands of open short positions. It may be prudent for retail shorts to be vigilant at this point, as a potential squeeze, which may have an unignorable probability in this case, may wipe out their margin accounts and even leave them indebted for an indefinite amount to their brokers. (Nfa) $SLXN $KOD $KNRX

$CLRO Yesterday, almost SEVEN-TENTHS of the off-exchange trades involved short sales. Despite the continuous heavy shorting, likely mostly maintained by recycling the same borrowed shares, as available borrowable shares remain scarce, with a notably high CTB above 800%, they have been struggling to suppress the price. Even modest demand, whether from bargain hunters or prudent shorts covering positions before a potential squeeze, may drive discrete moves, given the float below 1M. It may be one of the tickers that merit closer monitoring. $FRGT $OLOX

$CLRO As expected, after so many days of scarcity in borrowable shares and many open short positions, the CTP has jumped to an exorbitant ~853% from an already high ~227%. Early-exiting shorts may still avoid being caught in a potential squeeze. However, those who are late to cover may risk losing an indefinite amount in their margin accounts. (nfa, dyodd)

$CLRO DATED SEPTEMBER 4, 2026 Minimum Offering: 2,857,143 Units Maximum Offering: 4,285,714 Units Each Unit consisting of one share of Common Stock and one Warrant to purchase one share of Common Stock ClearOne, Inc. We are offering, on a best-efforts basis, a minimum of 2,857,143 units (“Units”) and a maximum of 4,285,714 Units at a price of $3.50 per Unit. Each Unit consists of one share of our common stock, par value $0.001 per share (the “Common Stock”), and one warrant to purchase one share of Common Stock (“Warrant”).

9/28 WL -> Happy Monday! $CLRO (only interested back over $6, seems weak atm) $LABT (ww red/green back over $2.50, not expecting much) $MEDS (ww back over $4 for scalp plays) $PMAX (another red/green candidate back over $2.25) Not seeing much at all this morning with small caps. A few pop and drops in PM and had to be very quick to capture any profits. Hoping we see a stronger week with momentum, but still remaining VERY patient in these markets. Trade the plan. Happy Huntin'!

$CLRO I expect to see a significant improvement in my overall greenup this week, reaching approximately 50%. Next week, I will invest a fixed amount of 1244 USD to demonstrate consistently how building wealth over time can be achieved. It’s important to note that this account is unrelated to my actual trading activities. It serves solely as a means to illustrate the principles and strategies involved in successful investing.

$CLRO This stock should not be sold for less than $20; it involves a merger that is fair to all parties. Buy and hold until the merger takes place in the very near future.

$CLRO Gains were too high in premarket to make this an attractive regular market entry at the moment. Same goes for the other big gainers. $LFCR is making some nice gains now.

📊 Today's Highest Relative Volume $CLRO — 217.72x RVOL Move: +58% Volume: 16.0M (68.6K average) Market Cap: $15.0M $SCYX — 17.68x RVOL Move: +5% Volume: 5.2M (70.6K average) Market Cap: $29.1M $LABT — 7.23x RVOL Move: +18% Volume: 28.2M (901.4K average) Market Cap: $3.4M High relative volume highlights where market attention is concentrated. Which one are you watching? 👀 Not financial advice.

$CLRO ClearOne entered into a definitive merger agreement to acquire Cortigent, Inc. (a neurostimulation and brain-implant device subsidiary of Vivani Medical). Bulls view this transaction as an injection of proprietary med-tech IP into an existing Nasdaq-listed shell, fundamentally resetting the valuation narrative away from a declining audio-conferencing business toward high-multiple neuromodulation technology.

$CLRO The float is 800K and it looks pretty cheap. Any sudden volume on this could make it go back to that 10$ range, worth to keep it on your radar.

$CLRO that was disappointing, all that for 50 cents… hope it was worth it. Stupid, this thing should be holding 6 at this point.

$CLRO a very bullish looking chart-it isn't done yet-especially with EOM short-covering

$CLRO Daily chart setting up in a strong formation for a pop here. Top small cap watch for tomorrow 📈

Keep a close watch on ticker SGRX. 🚨 They have been hammering this down, but I think it's ready for a big reversal. The float is around 1M, if this gets enough volume we can see $3+ quick. $CLRO $KNRX $BNKK .. WW

$CLRO Did everyone just bank on KOD and just leave everything else alone? What a slow day.

$CLRO ouch got stopped out on this one. which ended in a big halt down! be smart to everyone holding

$CLRO CELLGENIC product supplies were RMTG’s largest H1 revenue stream at $3.37M, up 227% YoY and representing 50.6% of H1 revenue. The report identifies exosomes, MSCs, NK cells, allogeneic fibroblasts and other biologics among the company’s product lines.